Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dynavax Technologies reports strong Q4 earnings, eyes continued growth

Dynavax Technologies showcased robust financial performance, driven by the success of HEPLISAV-B and CpG 1018 adjuvant. Progress in clinical development and market share growth were notable achievements. Challenges include maintaining market growth amidst competition and regulatory changes, while opportunities exist in expanding product revenue and advancing vaccine programs.

Dynavax reports record revenue growth, eyes market expansion opportunities

Dynavax Technologies showcased robust performance in Q1 2023, driven by record revenue growth and strong financial results.
While facing challenges such as uncertainties and competition, the company's strategic strengths and opportunities position it for continued success.
Management's focus on innovation, market expansion, and financial stability bodes well for future growth and shareholder value.
Overall, Dynavax Technologies remains optimistic about its outlook, supported by a dedicated team and a solid commercialization strategy.

Dynavax reports strong Q2 earnings, eyes growth through innovation

Dynavax Technologies delivered robust financial results in Q2 2023, driven by strong HEPLISAV-B revenue growth and increased market share.
The company's focus on innovation, market expansion, and financial stability positions it well for future growth and strategic opportunities.
While facing challenges in revenue sustainability and competition, Dynavax's strengths in market penetration and product pipeline offer avenues for continued success.
By leveraging opportunities in market expansion, product diversification, and strategic partnerships, Dynavax can further solidify its position in the vaccine and infectious disease spaces.

Dynavax reports record revenue growth and raises full-year guidance

Dynavax Technologies delivered a strong performance in Q3 2023, driven by record HEPLISAV-B revenue and market share gains.
While facing margin pressures from increasing expenses, the company's strategic focus on diversification and innovation bodes well for future growth.
With raised revenue guidance, a robust clinical pipeline, and a solid financial position, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports record revenue growth and strategic investments

Dynavax Technologies' Q4 2023 earnings call highlighted robust revenue growth, market leadership, and strategic investments in HEPLISAV-B.
The company's financial outlook for 2024, including revenue guidance and expense projections, reflects a balanced approach to growth and profitability.
With a strong cash position, ongoing pipeline developments, and focus on cost management, Dynavax is poised for continued success and market expansion.

Dynavax Technologies reports robust Q1 earnings and growth outlook

Dynavax Technologies delivered solid financial results in Q1 2024, driven by continued growth in HEPLISAV-B net product revenue and a focus on innovation and R&D advancement.
Despite market challenges and expenses, the company's strong cash position, market leadership, and upcoming milestones position it well for sustainable growth and success.
With a clear strategic focus on driving growth, maintaining market share, and advancing its vaccine portfolio, Dynavax is poised for a promising future in the healthcare industry.

Dynavax reports record sales and market share gains in Q2 2024

Dynavax Technologies delivered strong financial performance in Q2 2024, driven by record HEPLISAV-B sales and market share gains.
The company's pipeline progress and robust cash position position it well for future growth and innovation.
While challenges in managing expenses persist, strategic opportunities and a positive outlook for HEPLISAV-B offer avenues for sustained success.
Dynavax's focus on cost management, market expansion, and product development will be key to capitalizing on opportunities and overcoming challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EMERYVILLE, Calif., May  21, 2020  (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.  Dynavax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common stock being offered in the public offering.  All of the shares in the offering will be sold by Dynavax. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Dynavax Technologies Announces Proposed Public Offering of Common Stock

Atara Biotherapeutics

Homology Medicines

G1 Therapeutics

ImmunoGen

Kadmon Hlds

Viking Therapeutics

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

7 Biotech Stocks Wall Street Says Will Double or More

Dynavax's COVID-19 vaccine program is turning heads this morning.

Why Dynavax Technologies Is Jumping Today

Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Dynavax Technologies (DVAX) Stock Might be a Great Pick

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q1 2020 Results - Earnings Call Transcript

Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Agenus

Verastem

Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.

3 Top Stocks Under $5 to Buy Now

In the current market session, Dynavax Technologies Inc. (NASDAQ: DVAX) is trading at $3.40, after a 4.9% rise.

Price Over Earnings Overview: Dynavax Technologies

Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher

EMERYVILLE, Calif., April  16, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and  Sinovac Biotech Ltd.  (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that they have entered into a collaboration to develop a vaccine to prevent COVID-19. The collaboration will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018 ™.

Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine

The U.S. FDA approved vaccine is being provided to help protect critical healthcare workers in emergency medical settings from hepatitis B infections

Dynavax Donates 10,000 Doses of HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Vaccine to Emergency Healthcare Providers and Hospital Staff to Protect Against Hepatitis B Infections Amidst COVID-19 Pandemic

EMERYVILLE, Calif., April  02, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today provided a business update in relation to the impact of COVID-19 on the Company’s operations.

Dynavax Provides Business Update on COVID-19 Pandemic Impact

Shares of Dynavax Technologies Corp. DVAX, +7.25% gained 10% in trading on Thursday

Dynavax's stock rises 10% on expanded CEPI partnership

Dynavax Technologies Corp. (NASDAQ: DVAX) shares made a handy gain on Thursday after the company announced that it would be entering the coronavirus vaccine business.

Dynavax New Vaccine: Are Investors Sick of Coronavirus Vaccine Stocks Yet?

Dynavax to provide CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of COVID-19 vaccines Dynavax to provide CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of COVID-19 vaccines

Dynavax and CEPI Announce Collaboration to Support Global Effort to Develop a Vaccine for Coronavirus (COVID-19)

EMERYVILLE, Calif. and CHENGDU, China, March  24, 2020  (GLOBE NEWSWIRE) --  Dynavax Technologies Corporation  (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and  Clover Biopharmaceuticals , a China-based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, today announced that they have entered into a research collaboration to develop a vaccine candidate to prevent COVID-19.  Clover is advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) in preclinical studies.  Dynavax is providing technical expertise and the company’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018, to support this initiative.

Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -3.03% and -11.29%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Reports Q4 Loss, Misses Revenue Estimates

Dynavax Technologies (NASDAQ:DVAX) reported Q4 results. Quarterly Results • Earnings per share were up 31.25% year over year to a loss of $0.44, which missed the estimate by $0.11.

Dynavax Technologies: Q4 Earnings Insights

Dynavax joins the race to develop a COVID-19 vaccine.

Why Dynavax Technologies Stock Is Surging Today

Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine Dynavax is providing CpG 1018, the adjuvant contained in HEPLISAV-B, to support the rapid development of a COVID-19 vaccine

Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Preparedness (CEPI) Focused on the Development of a Coronavirus (COVID-19) Vaccine

Dynavax's stock has continued to lose ground in 2020. Is it finally time to buy?

Is Dynavax Technologies Stock a  Buy ?

Can Dynavax's stock rebound after a dreadful 2019?

Why Dynavax Technologies Corporation Stock Cratered in 2019

Dynavax: Concentrating On Vaccines Could Stabilize The Investment

David Novack Appointed President and Chief Operating Officer David Novack Appointed President and Chief Operating Officer

Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors

- Partnership at 1,700 pharmacies nationwide with special focus on people living with diabetes  - People living with diabetes are two times more likely to become infected with hepatitis B virus and up to four times as likely to get HBV-related liver cancer

News for Dynavax Technologies Stock (DVAX)